Strategies for anti-fibrotic therapies.

@article{Rosenbloom2013StrategiesFA,
  title={Strategies for anti-fibrotic therapies.},
  author={Joel Rosenbloom and Fabian Mendoza and Sergio A Jimenez},
  journal={Biochimica et biophysica acta},
  year={2013},
  volume={1832 7},
  pages={1088-103}
}
The fibrotic diseases encompass a wide spectrum of entities including such multisystemic diseases as systemic sclerosis, nephrogenic systemic fibrosis and sclerodermatous graft versus host disease, as well as organ-specific disorders such as pulmonary, liver, and kidney fibrosis. Collectively, given the wide variety of affected organs, the chronic nature of the fibrotic processes, and the large number of individuals suffering their devastating effects, these diseases pose one of the most… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 46 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 310 references

Cat-192 Study Group; Scleroderma Clinical Trials Consortium

  • C. P. Denton, P. A. Merkel, +7 authors J. R. Seibold
  • Recombinant human anti-transforming growth factor…
  • 2007
Highly Influential
5 Excerpts

Characterization of SIS3

  • W. Jinnin, H. Ihn, K. Tomaki
  • a novel specific inhibitor of Smad3, and its…
  • 2006
Highly Influential
6 Excerpts

Similar Papers

Loading similar papers…